FIALA, Ondrej, Pavel OSTASOV, Ondrej SOREJS, Vaclav LISKA, Tomáš BÜCHLER, Alexandr POPRACH and Jindrich FINEK. Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients. Cancers. BASEL: MDPI, 2019, vol. 11, No 12, p. 1-13. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers11121856. |
Other formats:
BibTeX
LaTeX
RIS
@article{1623236, author = {Fiala, Ondrej and Ostasov, Pavel and Sorejs, Ondrej and Liska, Vaclav and Büchler, Tomáš and Poprach, Alexandr and Finek, Jindrich}, article_location = {BASEL}, article_number = {12}, doi = {http://dx.doi.org/10.3390/cancers11121856}, keywords = {colorectal cancer; bevacizumab; beta-blocker; outcome; hypertension}, language = {eng}, issn = {2072-6694}, journal = {Cancers}, title = {Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients}, url = {http://dx.doi.org/10.3390/cancers11121856}, volume = {11}, year = {2019} }
TY - JOUR ID - 1623236 AU - Fiala, Ondrej - Ostasov, Pavel - Sorejs, Ondrej - Liska, Vaclav - Büchler, Tomáš - Poprach, Alexandr - Finek, Jindrich PY - 2019 TI - Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients JF - Cancers VL - 11 IS - 12 SP - 1-13 EP - 1-13 PB - MDPI SN - 20726694 KW - colorectal cancer KW - bevacizumab KW - beta-blocker KW - outcome KW - hypertension UR - http://dx.doi.org/10.3390/cancers11121856 L2 - http://dx.doi.org/10.3390/cancers11121856 N2 - Background: Beta-adrenergic signalling plays an important role in several cancer-related processes, including angiogenesis. The impact of beta-blocker use on prognosis of cancer patients treated with antiangiogenic agents is unclear. The aim of this study was to evaluate the association between the incidental use of beta-blockers and the outcomes of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab-based therapy. Methods: Clinical data from 514 mCRC patients treated with bevacizumab between 2005 and 2019 were analysed retrospectively. The association of progression-free survival (PFS) and overall survival (OS) with the incidental use of beta-blockers and other common antihypertensive drugs was assessed. Results: The median PFS and OS for patients using beta-blockers was 11.40 (95% confidence interval (CI) 10.10-13.61) months and 26.8 (95% CI 22.2-32.2) months compared with 8.30 (95% CI 7.80-9.57) and 21.0 (95% CI 17.8-23.8) months for patients not using beta-blockers (p = 0.006 and p = 0.009, respectively). In the Cox multivariate analysis, the use of beta-blockers was a significant factor predicting both PFS (hazard ratio (HR) = 0.763 (95% CI 0.606-0.960), p = 0.021) and OS (HR = 0.730 (95% CI 0.560-0.951), p = 0.020). Conclusions: The results of the present retrospective study suggest that there is a significant association between the use of beta-blockers and favourable outcomes of mCRC patients treated with bevacizumab-based therapy. ER -
FIALA, Ondrej, Pavel OSTASOV, Ondrej SOREJS, Vaclav LISKA, Tomáš BÜCHLER, Alexandr POPRACH and Jindrich FINEK. Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients. \textit{Cancers}. BASEL: MDPI, 2019, vol.~11, No~12, p.~1-13. ISSN~2072-6694. Available from: https://dx.doi.org/10.3390/cancers11121856.
|